HomeAI · summaries
Storia in 2 fonti
Agenus surges on study pivot; Apnimed lines up an IPO
Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Agenus surges on study pivot; Apnimed lines up an IPO
Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an…
- ·
benzinga.com
Why Is Agenus Stock Gaining Monday? - Agenus (NASDAQ:AGEN)
Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.